Clinical trials: Non-Hodgkin
Chronic Lymphocytic Leukemia, B-cell Lymphomas
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
- Trial name
- NCT02891590
- Testing
- DTRMWXHS-12
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang DTRM Biopharma
Mantle Cell Lymphoma
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
This study is evaluating the efficacy of acalabrutinib in combination with rituximab (Arm 1) versus ibrutinib (Arm 2) versus acalabrutinib (Arm 3) for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL).
- Trial name
- NCT02735876
- Testing
- acalabrutinib, ibrutinib, rituximab
- Sponsor
- Acerta Pharma BV
Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma
- Trial name
- CD205SHUTTLE (NCT03403725)
- Testing
- MEN1309
- Where
- 7 sites in Belgium, Italy and 2 more
- Volunteers
- 28 people
- Sponsor
- Menarini Group
Lymphoma, Large B-Cell, Diffuse
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and…
- Trial name
- ROBUST (NCT02285062)
- Testing
- lenalidomide, Rituximab, Cyclophosphamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 570 people
- Sponsor
- Celgene
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell…
- Trial name
- NCT05934513
- Testing
- GFH009
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Follicular Lymphoma
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1…
- Trial name
- NCT04762160
- Testing
- Tazemetostat, Rituximab
- Where
- 20 sites in United States
- Volunteers
- 5 people
- Sponsor
- Epizyme, Inc.
Lymphoma, B-Cell
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
This is a phase 1 trial designed to evaluate safety and tolerability of chemotherapy in combination with inotuzumab ozogamicin, an investigational product, in adults with CD22-positive non-Hodgkin's lymphoma.
- Trial name
- NCT01055496
- Testing
- inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone, inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
- Where
- 28 sites in United States, Belgium and 7 more
- Volunteers
- 103 people
- Sponsor
- Pfizer
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Degenerative Disc Disease, Spondylolisthesis, Grade 1
AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY
This is a post-market clinical study of the AccuLIF expandable transforaminal lumbar interbody fusion (TLIF) cage in patients requiring surgery for degenerative disc disease (DDD) with up to Grade I spondylolisthesis or…
- Conditions
- Degenerative Disc Disease, Spondylolisthesis, Grade 1, Retrolisthesis
- Trial name
- APROPOS (NCT02704689)
- Testing
- AccuLIF expandable TLIF cage
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VB Spine, LLC
Solid Tumors, Acute Myeloid Leukemia
A Study of PLX51107 in Advanced Malignancies
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced…
- Conditions
- Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02683395
- Testing
- PLX51107
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Plexxikon
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
- Trial name
- NCT06909877
- Testing
- HH2853 Tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Haihe Biopharma Co., Ltd.
ALK-activated Tumors
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
The purpose of this study was to estimate the maximum tolerated dose and/or recommended dose for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose…
- Trial name
- NCT01742286
- Testing
- Ceritinib
- Where
- 23 sites in United States, Australia and 8 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Tinnitus
Sub-chronic Neurostimulation Delivered in the Middle Ear for Tinnitus Suppression
The objectives of this study are to evaluate the safety and efficacy of applying electrical stimulation on the promontorium (EPS) for the suppression of tinnitus in a sub-chronic stimulation regimen.
- Trial name
- NCT01549145
- Testing
- Nimbus Multifunctional Stimulator
- Where
- Israel
- Volunteers
- 14 people
- Sponsor
- EstimME Ltd.
Relapsed/Refractory Aggressive B-cell Lymphomas
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy.
- Trial name
- NCT02271945
- Testing
- MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- MedImmune LLC
Relapsed Solid Tumors, Refractory Solid Tumors
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).
- Conditions
- Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC
- Trial name
- NCT04718675
- Testing
- KB-0742
- Where
- 24 sites in United States, Spain and 1 more
- Volunteers
- 135 people
- Sponsor
- Kronos Bio
B-cell Non-Hodgkin Lymphoma
A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D).
- Trial name
- NCT07661537
- Testing
- SHR-3079 Injection
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1
Pedicle Osteotomy for Stenosis Trial
This is a pivotal Randomized Clinical trial to compare the safety and effectiveness of the Pedicle Lengthening Osteotomy Procedure with implantation of the Altum® Device to open surgical decompression and Transforaminal Lumbar…
- Conditions
- Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1, Neurogenic Claudication
- Trial name
- POST (NCT03381677)
- Testing
- Pedicle Lengthening Osteotomy with Altum® Device, Control
- Where
- United States
- Volunteers
- 344 people
- Sponsor
- Innovative Surgical Designs
Mantle Cell Lymphoma
HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma
This is a Phase Ib/III, multicenter, open-label clinical study of HDM2005 in combination with rituximab and lenalidomide in adult patients with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT07697339
- Testing
- Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len, Rituximab plus lenalidomide, Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len
- Volunteers
- 40 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
Single center, pilot study to evaluate the safety and efficacy topical administration of WP1220 in subjects with Stage I, II or III Mycosis Fungoides (CTCL)
- Trial name
- NCT04702503
- Testing
- WP1220
- Where
- Poland
- Volunteers
- 5 people
- Sponsor
- Moleculin Biotech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.